Analyses Exposition-Réponse de l'Efficacité et de l'Innocuité de l'Upadacitinib Dans des Études de Phases 2 et 3 Pour Étayer l'Évaluation Bénéfices-Risques Dans la Polyarthrite Rhumatoïde
Clin Pharmacol Ther . 2020 Apr;107(4):994-1003. doi: 10.1002/cpt.1671.
UPA 15 mg provided the optimal benefit-risk in RA through maximizing efficacy with only small incremental benefit with 30 mg, and with consistency across RA subpopulations and with UPA monotherapy or combination with csDMARDs. Exposure-response analyses were conducted using combined data from two Phase 2b and five Phase 3 studies in order to characterise the relationship between plasma exposure and efficacy, as well as to select safety parameters using the totality of the data in subjects with R...